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1. INTRODUCTION 
 
As a result of an aging population, changes in lifestyle, and higher level of obesity, 
diabetes affects an increasing number of patients, and their number is expected to more than 
double worldwide by the year 2030 [1].  There are nearly half million registered diabetic 
patients in Hungary, but the number of people affected is thought to be much higher; the 
estimated prevalence of diabetes among adults was 9.7% in Hungary in 2003, one of the 
highest values in Europe (Figure 1) [2, 3]. The vast majority of patients, 85-95%, have type 
2 diabetes [3].  An increased blood glucose level is associated with a greater risk of 
microvascular and macrovascular complications.  It has been reported that macroangiopathy 
can effect up to one-third of patients diagnosed with type 2 diabetes [4].  These 
complications not only diminish patients’ health and result in decreased quality of life, but 
also put a high financial burden on the health care system [5].  The United Kingdom 
Prospective Diabetes Study clearly proved the benefits of intensive glycemic control in 
patients with type 2 diabetes [6].  Previous studies have also shown that increased adherence 
to oral antidiabetic drugs results in better metabolic control and, consequently, in decreased 
hospitalization rates and lower total annual health care costs [7–9]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.   Estimated prevalence of diabetes among the adult population in the European 
countries in 2003 [3]. 
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The successful treatment of diabetic patients require a multidisciplinary approach, 
involving diabetologists, general practitioners, pharmacists, nurses, dieticians and 
psychologists.  During the past decades several countries implemented pharmaceutical care 
programs targeting diabetic patients, and such a program is presently in its developmental 
phase in Hungary.  
The thorough design of the care programs necessitates the detailed studying and 
understanding of past and present trends in the treatment of the disease, and the investigation 
of patients’ behavior in order to optimize future therapeutic outcomes and to lower health 
care expenditures.  Pharmacoepidemiologic studies provide valuable information regarding 
the uses and effects of pharmacological treatment in a defined time, space and population 
[10]. 
The purpose of the present study was to investigate the escalation of diabetes in 
Csongrád County and to evaluate the pharmacological treatment of patients, through patient 
specific population level data applying pharmacoepidemiologic methods. 
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2.  BACKGROUND 
 
2.1. Pharmacoepidemiology 
 
Pharmacoepidemiology is the study of the utilization and effects (beneficial and 
adverse) of drugs in large numbers of people.  Its main goal is to describe, explain and 
forecast the use and effects of pharmacologic treatments in a defined time, space and 
population [10].  Pharmacoepidemiology is referred to as a bridge science as it blends 
clinical pharmacology and epidemiology through the application of epidemiological methods 
to pharmacological matters [11].  Pharmacoepidemiologic studies can supply information on 
various features of medication utilization and prescribing: pattern of use, quality of use, 
determinants of use, and outcomes of use [12].  The ultimate purpose of 
pharmacoepidemiologic research is to enhance the rational medication use of the population; 
where rational use means the application of a well-documented drug at an optimal dose, 
together with the correct information and at an affordable price [13].  National drug policies 
should be based on – and regularly reevaluated on the bases of – the results of 
comprehensive national drug utilization data [14].  Pharmacoepidemiologic studies can 
identify the areas that require attention and action, but they do not necessarily offer the 
solutions for the problems [12].   
Pharmacoepidemiology is a relatively new branch of pharmaceutical sciences, it roots 
from the 1960s, when early drug utilization studies were performed in Northern Europe and 
Great Britain [12].  It was soon recognized that data of different studies and countries were 
not comparable as they used different methodologies and units to measure drug use.  In 
1969, at the symposium entitled ‘The Consumption of Drugs’ organized by the World 
Health Organization (WHO) Regional Office for Europe, the Drug Utilization Research 
Group (DURG) was established and appointed with the development of internationally 
applicable drug utilization methods [15].  In the mid 1970s, for the classification of 
medication, Norwegian researchers developed the Anatomic Therapeutic Chemical 
Classification (ATC), and for the measurement unit the Defined Daily Dose (DDD) was 
introduced to be used in drug statistics [15].  In 1981, the ATC/DDD system was proposed 
by the WHO Regional Office for Europe for international drug utilization studies. The 
following year, in 1982, and the WHO Collaborating Centre for Drug Statistics was 
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established, with the purpose of coordinating the use of the ATC/DDD system [14].  In 
1996, WHO realized that the ATC/DDD system should be implemented and used outside of 
Europe, as well, and the expert panel of WHO International Working Group for Drug 
Statistics Methodology was founded to facilitate the globalization of the ATC/DDD system.   
 
2.1.1. The ATC/DDD methodology 
 
The ATC classification is a five level, seven digit coding system.  Drugs are 
categorized into 14 main (anatomic) groups (1st level) based on the targeted organ (Table 1).  
The 2nd level of the classification is based on the drug’s main therapeutic category, while the 
3rd level refers to the pharmacological subgroup. The 4th level is the 
chemical/pharmacological/therapeutic subgroup, and the 5th level is the chemical substance.  
Pharmaceutical products are classified in the ATC system according to their main 
therapeutic indication.  An active ingredient can be classified under more than one ATC 
codes, if it is marketed in different strength and/or formulation with clearly different 
therapeutic uses [15].  New agents can be easily added to the system. 
 
 
A Alimentary tract and metabolism 
B Blood and blood forming organs 
C Cardiovascular system  
D Dermatologicals 
G Genito urinary system and sex hormones 
H Systemic hormonal preparations, excl. sex hormones and insulins 
J Anti-infectives for systemic use 
L Antineoplastic and immunomodulating agents 
M Musculo-skeletal system 
N Nervous system 
P Antiparasitic products, insecticides and repellents 
R Respiratory system 
S Sensory organs 
V Various 
 
Table 1.  ATC main (anatomic) groups 
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DDD is the average daily maintenance dose of the medication in its main therapeutic 
indication.  DDD is initially based on the manufacturers’ recommendation, and after 
marketing, it is regularly reevaluated (in every 3 years) on the bases of actual prescribed 
daily doses [14].  The medication use of large populations is often expressed as the number 
of DDDs per 1000 inhabitants per day (DDD/1000 inhabitants/day), which technical unit 
enables researches to compare the drug use of populations of different sizes [13].   
 
2.1.2. Pharmacoepidemiology in Hungary 
 
According to the 12/1978 ordinance of the Ministry of Health, the National Institute 
of Pharmacy (OGYI) was appointed to execute the adaptation of the ATC/DDD system, and 
to perform national drug utilization statistics in Hungary.  The ATC classification has 
become widely known and used (medication compendiums include the ATC codes), but the 
DDD is still seldom used for drug utilization studies.  Most statistics rather focus on the 
financial aspect of drug uses, and often, as a measuring unit, the number of boxes is used, 
which greatly jeopardize the comparability of the studies.  
Beside the official drug utilization duties of the OGYI, a few clinical pharmacists 
took the initiatives in the country, and have carried out valuable drug utilization studies [16].  
Some university research groups have also performed quality pharmacoepidemiologic 
research. 
Most of these studies provide an overall view on the nation’s consumption of some 
specific groups of medication (e.g. antiepileptic drugs, antimicrobial drugs), but they lack 
patient specific information, which would allow for more in-depth analyses. 
There has been a few studies were previously published on the antidiabetic drug 
utilization in Hungary [17–21], but only one had some patient specific information on a 
research cohort of limited size and time span [21]. 
The present pharmacoepidemiologic research on oral antidiabetic drugs is the first of 
its size in Hungary, which analyzes patient specific data of a large population (430.000 
inhabitants) over a 7 year period. 
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2.2. Data sources for pharmacoepidemiologic studies and their availability in Hungary 
 
Pharmacoepidemiologic studies are only as appropriate and accurate as the data 
source they are based on.  Study set up should be carefully designed, and the pros and cons 
of the different data sources must be taken into consideration.  Every data source has its 
limitations, but the integration of data from different sources provides more thorough 
information about health events.  Several types of data sources that are commonly used in 
pharmacoepidemiologic studies are summarized below. 
 
2.2.1. Wholesale database 
 
Drug wholesale data provide information on the medication – including both 
prescription and over-the-counter (OTC) drugs – supplied to pharmacies.  If data from every 
wholesaler in a country are compiled, the complete medication use of the country is given.  
In Hungary complete drug sale information based on wholesaler data was managed and was 
available from PharmMIS Consulting Company until 2004, and since then IMS has been 
providing similar services.  IMS is the leading pharmaceutical market research company 
present in over 100 countries worldwide.  
An advantage of the above database is that it distinguishes between retail and 
institutional pharmacies, therefore the medication use of the general population and that of 
hospitals can be studied separately.  However, as these data are not patient-specific, they 
only give a general overview of a country’s drug consumption, and do not supply 
information on the individual drug use of patients.  Wholesale database is a slight 
overestimation of a nation’s medication use, as it measures the amount of drug shipped to 
the pharmacies, but does not take into consideration the fact that some medication is 
discarded by the pharmacy and does not reach the patients.  Moreover, some of the 
medication bought in Hungary is actually used by patients in neighboring countries. 
 
2.2.2.  Pharmacy database 
 
In several countries pharmacies maintain Patient Medication Record (PMR), with the 
purpose of supplying the dispensing pharmacist with valuable information on the patients’ 
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medication history, and, consequently, aiding the delivery of high level pharmaceutical care.  
The International Pharmaceutical Federation (FIP) recommends the maintenance of the 
PMR, because it is an essential requirement for the implementation of pharmaceutical care as 
described in the FIP Statement of Professional Standards on Pharmaceutical Care issued in 
1998 [22]. With the introduction of computers in pharmacies these databases became 
electronic.   
These databases are usually limited to prescription only medication, but in some 
cases they also include OTCs.  Some PMRs do not only provide information on the 
mediation use of the patients, but may also include data on the patients’ health history, 
diseases and allergies.  The pharmacy based PMRs are unable to capture any medication 
acquired in other pharmacies, and, consequently, impair the quality of pharmaceutical care.  
Recognizing the limitations arising from the fragmentation of information on patients’ 
medication use, some countries (e.g. Canada) set up centralized pharmacy databases which 
can be accessed by every pharmacy [23].   
In Hungary pharmacies do not maintain such databases, although some pharmacy 
softwares are able to store the information on the dispensed prescriptions.  
The manual review of prescriptions accumulated at pharmacies is also an optional 
data source for pharmacoepidemiologic studies, although manual reviewing is a very time 
consuming process.  
 
2.2.3.  Medical database 
 
General practitioners (GP) maintain a detailed medical history of their patients. A 
great advantage of these databases is that, beside the prescribed medication, thorough 
information on the patients’ health status is also available.  These databases supply the 
prescribed daily dose (PDD), which provide very useful information for some types of 
pharmacoepidemiologic analyses. The completeness of these databases is limited by the fact 
that they may not include medication prescribed by other doctors. A further limitation is that 
they do not necessarily represent the actual medication use of the patients, because they 
record only the fact of prescribing, but it is well known that patients do not always claim 
their prescriptions. 
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In 2005 the UK launched its new centralized patient record database to which every 
GP is connected, and supplying medical data on their patients [24].  This is the first database 
of its kind in the world which will provide comprehensive medical information on a nation’s 
health status, and thus, among several other functions, it will become a precious source for 
health statistics.  
 
2.2.4.  Patient interview 
 
Directly interviewing the patients about their medication use does not only give 
valuable information on the prescription and OTC drugs, but also on any supplements and 
herbal remedies.  They can provide data on any medication patients use regardless of the 
source they acquired them from (even if they use any medication that was originally 
prescribed to someone else). Through direct interview data on the socioeconomic 
background (eg. level of education, income, housing) of the patients can be recorded, which 
otherwise would not be available, and which can effect and explain some of the medication 
use pattern.  As patients may use drugs differently from how they were instructed by doctors 
or pharmacists, interviewing is the method that can give the closest picture of the actual 
medication use of patients. 
Interviewing patients is generally a time consuming process, therefore it is usually 
not feasible to include large number of subjects.  As limited number of subjects are involved, 
careful sampling is essential to ensure that the results are representative. 
The accuracy of information collected by interviewing patients may be limited by the 
fact that most patients are not drug experts, therefore they tend to provide incomplete 
information about their medication. Also, during a face to face discussion patients may not 
disclose all details of their health concerns.  Some patients may purposely report misleading 
information. 
 
2.2.5. Insurance database 
 
Insurance drug claims databases consist of prescriptions dispensed to their insured 
clients. In several countries these databases only accumulate information on prescriptions 
that were reimbursed at some extent by the insurance company, and therefore have no data 
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on non-reimbursed prescriptions.  If health insurance is not mandatory in a country, then the 
insurance database reflects the drug use of that special segment of the population which can 
afford to have health insurance, so its results have to be used with caution and cannot be 
extrapolated to the entire population.  Insurance databases collect data on the dispensation of 
the prescriptions, but have no information on the actual consumption of the medicine.  It is 
also possible that the medication is taken by someone different from whom the medication 
was originally prescribed to.  Accumulating data on a nation’s drug use based on insurance 
databases becomes difficult if more than one health insurance company operate in a country. 
In Hungary basically every citizen is covered by national health insurance, and the 
Hungarian National Health Insurance Fund Administration is the single national health 
insurance company.  Its prescription claims database provides a complete history of the 
prescription drug use of the population at the patient level.  Further details of the database 
are described under section 4.1.  
 
2.3. Patient cooperation 
 
It is well recognized that the mere prescribing of medications does not necessarily 
result in the desired improvement in the patients’ health.  Often, the failure is not due to the 
inappropriate selection of the medication, but rather, to the inappropriate use of the drug.  
The maximal beneficial effect of a treatment plan can only be achieved if patients strictly 
comply with the recommendations, although, in reality, they often fail to do so, which leads 
to suboptimal clinical benefit and complications of the disease, wastes health care resources 
through increased treatment cost and increased hospitalization rate, and reduces patients’ 
quality of life [25, 26].  These serious consequences justify the necessity of extensive 
research of the issue.   
Several terms – such as compliance, adherence, persistence – have been used during 
the past decades to describe the extent at which the prescribed treatment was followed.  
Compliance is defined as the extent to which the patient follows medical instructions [25].  
Medical instructions refer not only to the use of medication or medical devices, but also to 
dietary and lifestyle recommendations.  The above definition views the patient as a passive 
subject in the process, although active cooperation of the patient is essential.  Therefore the 
term was redefined and the expression of adherence was introduced.  Adherence is defined 
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as the extent to which a person’s behavior corresponds with agreed recommendations from a 
health care provider as agreed upon through a shared decision-making process between the 
patient and the health care provider [25].  Adherence involves a mutual decision-making 
process between the patient and the health care provider. This definition recognized the 
importance of the patient’s active contribution to the development of the treatment plans.  
While the difference between the definition of compliance and that of adherence is evident, 
in the scientific literature they are rarely defined clearly and they are often used 
interchangeably [27]. 
While compliance and adherence describe the quality of medication taking behavior 
of the patient, persistence is rather focusing on the length of the therapy.  Persistence is 
defined as the time between the first and last doses taken [28].  In most persistence studies 
treatment cessation is defined as nonrenewal of a prescription within a grace period of a 
specified length (usually ranging between 30 and 180 days) after the end of the last 
prescription [29–31].  A gap in the course of the treatment may not actually indicate the 
discontinuation of the therapy, but rather a ‘drug-holiday’, therefore application of a grace 
period of any length may lead to false persistence results.  Resent research strongly 
discourages the use of a grace period as an indicator of therapy discontinuation, and advices 
to use the time period between the first and the very last prescription as the persistence, 
regardless of any gaps in the course of treatment [28].  As persistence describes the 
continuity of the treatment over an extensive period of time, persistence studies are only 
applied in cases of long term therapies, and not in cases of acute treatments. 
 
2.3.1. Measuring adherence 
 
Adherence rate is the extent to which patients’ behavior corresponds with the 
prescribed treatment plan, expressed in percentages.  Adherence can vary between 0 and 100 
percent, or even over 100 percent, when the patient is using more medication than 
prescribed.  Although adherence is a continuous variable, most research use adherence as a 
dichotomous variable and categorize patients as being either adherent or nonadherent [32].  
There is no set standard of what to be considered as adequate adherence.  Many of the 
adherence studies apply an 80% breakpoint, and consider rates over 80% to be adequate [7, 
33], while lower  breakpoint value can be found in the literature, as well [34].  Some 
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research do not only set the accepted low level, but an upper limit is also defined (110 or 
120%), above which patients are also classified as nonadherent, recognizing that not only the 
underuse, but also the overuse of the medication can result in undesired health outcomes [35, 
36]; although the underuse of medications is much more common than the overuse [37]. The 
level of the acceptable adherence rate should be carefully considered for each research study 
individually, and should be based on how much the therapeutic outcome is affected by the 
decreased adherence.  In studies focusing on the treatment of cancers or HIV/AIDS, where 
extremely strict adherence is crucial in achieving desired outcomes, the level of good 
adherence is set at 90 or 95% [36, 38, 39].  
Although there are several methods available for the assessment of adherence, it is 
difficult to obtain accurate measurements, and the techniques are rather estimating than 
precisely measuring adherence rate.  Methods should be carefully selected and the results 
should be evaluated with caution. The application of more than one adherence measuring 
methods in a study may compensate for the weaknesses of the different approaches and can 
provide a more realistic result.  In precisely designed clinical trials adherence can be 
exceptionally high, due to the strict patient inclusion criteria and the high level of attention 
patient receive [40].  Therefore, the results of such studies cannot be extrapolated to the 
general population in everyday setting.  
The techniques of measuring adherence ranges from patients’ self report to highly 
sophisticated electronic monitoring devices [25]. 
Patient self-report is a convenient and inexpensive method, but its reliability is 
jeopardized by the fact that patients tend to overestimate their own adherence, as they may 
inaccurately recall their medication taking behavior, or they simply want to please the health 
care provider and avoid possible conflicts with him [37]. 
Doctors’ estimation of their patients’ adherence has been used in some clinical trials, 
and could also play an important role in everyday practice in the identification of patients 
who require intervention to have their adherence improved.  Unfortunately, doctors tend to 
overestimate patients’ cooperation and they are inadequately detect poor adherence [41].  
Pill count technique is based on counting the remaining number of doses on the next 
clinic or pharmacy visit.  Adherence is often overestimated as patients may remove 
remaining pills before the visit.  Data can be distorted if patients take pills that remained 
from a previous refill. 
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The analyses of pharmacy records can be used as a simple and cheap way of 
assessing adherence.  From the amount of dispensed drugs and the refill frequency adherence 
can be calculated, therefore this method is applicable only in cases of chronic health 
concerns that require long term continuous treatment.  The accuracy of this approach is 
limited by the lack of information on whether the patient actually ingested the medication or 
not.  Also, patients may obtain medication from other sources, which could not be detected.  
The advantages of the method are the relatively large number of subject that can be easily 
studied, and as the patients are not aware of the study, their behavior is not modified in the 
research setting, rather reflects their usual medication use. 
Biochemical analyses measure the concentration of the drug or its metabolites, or of 
an added inactive trace chemical from blood or urine samples.  These methods are expensive 
and may only be used in clinical settings.  Although biochemical analyses are the only 
methods that can definitively prove the ingestion of the medication, they can only give 
information about the drug use for a short period of time, which is less than the elimination 
time of the drug. 
Electronic devices, such as the Medication Event Monitoring System (MEMS), were 
developed to ensure an accurate monitoring of medication use.  MEMS is a special pill box, 
containing a microchip in its cap, which records the exact time and date of each opening of 
the bottle, and, consequently, the time of the medication taking, assuming that the 
medication is taken at the time of opening [42]. This technique allows the detection of even 
minor deviations from the recommended therapeutic plan, and the exact time frames of 
nonadherent periods can be identified. However,their high price greatly limits the use of 
such devices. 
 
2.3.2.  Improving adherence 
 
Improved adherence results in positive health outcomes and, consequently, in 
lowered health care expenditures [43–45].  There are several intervention methods available 
aiming at increasing patients’ adherence, and, consequently, optimizing health outcomes.  
Improving short-term adherence is relatively successful, but improving adherence in long-
term chronic diseases is difficult and not very effective [46].  Patients with acute health 
problems usually have higher adherence rates than those who are treated for chronic health 
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conditions [40].  Although nonadherence cannot be simply overcome by quantifying the 
level of adherence, factors that lead to poor adherence must be identified and addressed.  
Nonadherence can be attributed to one or more of the following reasons: socioeconomic-
related factors, health system-related factors, disease-related factors, therapy-related factors 
and patient-related factors [25].   Until the actual cause of nonadherence is understood and 
dealt with on an individual level, long term success cannot be achieved. It is common belief 
that nonadherence is mainly the result of forgetfulness, but it has been revealed that only one 
fourth of nonadherence can be attributed to forgetfulness, but in the majority of cases patient 
deliberately chose not to take the medication [47].  Deliberate nonadherence can be the result 
of one or more of several factors: having fear of or experiencing side effects; not believing 
that medication is necessary or effective; not being able to afford to purchase the medication; 
not knowing how to use the drug properly.   
Numerous adherence improving approaches are targeted to compensate poor memory 
[48].  Such methods include simple checklist reminder, special calendar blister packs, daily 
pillbox, or even reminding telephone calls or SMS.  Other methods should be employed 
when addressing deliberate nonadherence.  Patient education and motivation usually lead to 
improved adherence [40].  The education should be focused on both the health condition and 
the treatment, including basic information about the medication, proper timing, possible side 
effects and drug interactions, and the importance of adherence should be emphasized, as 
well.  The treatment should be tailored to the patient’s lifestyle to cause the lowest possible 
interruption in regular daily activities, and the drug regimen should be simplified. 
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3.  MAIN RESEARCH OBJECTIVES 
 
1. To investigate the quantitative and qualitative changes in the utilization of oral 
antidiabetic drugs (OAD) through patient level data between 1998 and 2004 in 
Csongrád County.  
 
2. To explore the trends in the prevalence and incidence of diabetes in Csongrád County 
through drug utilization data. 
 
3.  To reveal any seasonality in the onset of type 2 diabetes. 
 
4. To analyze patients’ adherence and persistence with OAD therapy, and to identify 
patient groups that require increased attention during a pharmaceutical care program. 
 
5. To assess the pattern of pharmacy visits of patients with type 2 diabetes, and to 
explore if the degree of patients’ loyalty to their pharmacy correlates with their 
adherence to antidiabetic therapy. 
 
6. To investigate the complexity and the financial burden of the pharmacological 
treatment of diabetes and its complications. 
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4.  RESEARCH SUBJECTS and METHODS 
 
4.1.  Research subjects and data source 
 
The primary study population included the entire 430.000 inhabitants of Csongrád 
County. From this population every OAD user was identified and the final research cohort 
included each and every patient for whom any OAD was dispensed in Csongrád County 
between 1998 and 2004.  38,855 patients met the inclusion criteria, and all of their 912,620 
prescriptions for OADs dispensed were retrieved from the electronic prescription drug 
claims database of the Hungarian National Health Fund Administration (HNHFA).  The 
database is considered valid and comprehensive because the HNHFA is the sole health 
insurance company in Hungary with which every citizen is registered and with which all 
pharmacies have contracts.  The database consists of all reimbursed and nonreimbursed 
dispensed prescriptions, therefore, it provides a complete history of the prescription drug use 
of the population at the patient level.  The database consists of the following information on 
all dispensed prescriptions: patients’ age and sex; unique IDs of the patient, dispensing 
pharmacy, and prescribing doctor; the town where the dispensing pharmacy is located; 
dispensing date; ATC code; code of the medicine (specific for trade name, pharmaceutical 
form, strength, and package size); number of packages; amount paid by the patient; and 
amount reimbursed by HNHFA.  The number of dispensed DDDs is not shown in the 
database, but it can be calculated from the data available.  The utilization of OADs in the 
region was expressed in defined daily doses per 1,000 inhabitants per day (DDD/TID). 
Beside the OAD use of the entire population, the complete prescription medication 
history of 1350 patients with newly diagnosed type 2 diabetes was analyzed for a 5-year 
period following the diagnosis, and for a 6-month period prior the diagnosis.  This cohort 
claimed a total of 342,854 prescriptions during the 60-month period of diabetes and 18,256 
prescriptions during the 6-month period prior the initiation of antidiabetic treatment.  The 
cohort included all patients with newly diagnosed type 2 diabetes, whose treatment was 
initiated with OAD between August 1998 and May 1999, and claimed at least one 
prescription for any type of medication in each year during the following 5-year period, 
indicating that the person was still alive, therefore requiring treatment.  Patients without any 
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antidiabetic medication use during the 6 months prior the first prescription were classified as 
newly diagnosed [49].  It is a critical part of the cohort definition to appropriately select the 
necessary length of the drug free period for identifying incidence users, as the length of the 
drug free period can substantially influence incidence measurement and cohort 
characteristics [50].  The waiting time distribution (a method first described by Hallas et al. 
for drug utilization research [51]) of the first occurrence of an oral antidiabetic medication 
prescription for a given patient from the beginning of 1998 reached a steady state after 6 
months in our database, which proves that the 6-month run-in period is appropriate  
(Figure 2). 
The first prescription for OAD was referred to as the index prescription, and all analyses 
were performed relative to the index date in case of the 1350 patients.  Conducting the study 
relative to an index date rather than through calendar date is often used [29, 49], which 
technique allows to follow the course of a treatment from the beginning, and patients with 
different start date can be grouped into the same cohort. Furthermore, the method can 
eliminate biases due to in-year initiation or discontinuation of the therapy, and seasonal 
variations are also leveled off if patients are selected over a longer period of time. 
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Figure 2. Waiting-time distribution. The histogram shows when oral antidiabetic drug 
(OAD) users appear for the first time from the beginning of 1998. The steady state indicates 
the real incident cases. 
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Although the HNHFA’s database is a valuable resource for pharmacoepidemiologic studies, 
it has some limitations.  The database includes no information on the prescribed daily doses 
(PDD) (dosage or number of days supplied) or the patients’ diagnoses (International 
Classification of Diseases [ICD] code).  The database consists of prescriptions dispensed in 
retail pharmacies, but it has no information of medicines used by inpatient departments.  
However, data from IMS, which gathers sales information from drug wholesalers, show that 
in Csongrád County the institutional use of OADs was less than 1.5% of the total utilization.  
This small amount, the use of which could not be linked to individual patients, is very 
unlikely to cause considerable distortion in the results of the research.  The town of 
residency of patients is not available, and it is possible that some patients who claimed their 
prescription in Csongrád County had a permanent residency outside of the county.  On the 
other hand, some residents of Csongrád County might have claimed some of their 
prescriptions in other counties.  This phenomenon is expected to be very marginal, as only 
less than 1 percent of the OAD prescriptions dispensed in Csongrád County were prescribed 
by doctors who were primarily registered in other counties. 
 
4.2.  Distinguishing between the types of diabetes 
 
As the indication for the medication (ICD code) was not available from the database, 
it was not possible to distinguish between type 1 and type 2 diabetes based on medical 
diagnosis.  When medical diagnosis is not available, differentiation based on age is 
commonly used.  It is an accepted approach to classify patients as having type 1 diabetes if 
they are diagnosed before the age of 30 or 35, and those whose disease developed after the 
age of 30 or 35 are defined as type 2 diabetics [52, 53].  Since the onset of type 2 diabetes is 
shifting to a younger age, and type 1 diabetes can, as well, develop after the age of 30, the 
above method may misclassify some of the patients [54, 55]. 
In the present research, for the classification process, not only the age, but also the 
type of treatment was taken into consideration.  According to the guidelines and product 
monographs, the pharmacological treatment of type 2 diabetes can be achieved by OADs, by 
insulin, or by the combination of OAD and insulin.  Insulin is the basis for the treatment of 
type 1 diabetes, although some of the OADs may be added to the therapeutic scheme; 
however, OADs alone are not suitable for the treatment [56, 57].  Therefore, patients who 
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receive OAD treatment without any insulin can be definitively defined as having type 2 
diabetes, while those being on insulin alone, or on the combination of insulin and OAD can 
have either type of diabetes, in which cases age should be taken into consideration.  For the 
two endpoints of the study period (1998 and 2004) the utilization of OADs and insulins were 
analyzed together.  Until the age of 40, the prevalence of patients using insulin (insulin alone 
or insulin plus OAD) remained nearly steady at each age group (splitted into 5-year 
categories), after which a sharp rise was evident.  Those patients above the steady prevalence 
level were classified as having type 2 diabetes.  Combining insulin with OAD is not a 
common practice, and under the age of 40 hardly any patient on insulin received OAD as 
well, indicating that OADs are almost never prescribed for patients with type 1 diabetes.  In 
conclusion, anyone receiving OAD or the combination of OAD and insulin was classified as 
having type 2 diabetes.  Based on the above criteria, of all patients receiving 
pharmacotherapy for diabetes, 6% had type 1 diabetes and 94% had type 2 diabetes.  These 
figures are in accordance with previously published international estimations, where the ratio 
of type 2 diabetes was assumed to be between 85 and 95% [3]. 
 
4.3.  Methods used for measuring adherence and persistence 
 
Adherence to OAD was defined using the medication possession ratio (MPR), a 
method commonly used to quantify medication adherence.  The MPR indicates the 
proportion of days for which the patient possessed a supply of medication [7].  
Nonadherence was set as MPR < 80%, which has been often used in the literature in cases of 
diabetes and other chronic diseases.  The mean MPR was calculated for patients receiving 
combination therapy.  The prescribed daily doses (PDD) were not recorded in the database; 
therefore, the WHO’s DDDs were applied as the assumed prescribed doses [58].  The 
method can be considered appropriate because its results correlated well with the outcomes 
of other adherence measuring method (refill frequency) executed on the same set of data.  In 
Hungary, as a general regulation, doctors were allowed to prescribe a 1-month supply of 
medication (which equals 30 PDDs), so patients should have claimed their prescriptions each 
month.  Refill frequency adherence was calculated as the number of months in a year in 
which the patients claimed at least one prescription for OAD, divided by 12.  The results 
yielded by the DDD and the refill frequency methods were compared by performing Pearson 
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correlation after Kolmogorov-Smirnov test for assessing normal distribution (R = 0.934, P = 
0.006), and paired t-test was applied to demonstrate that there were no significant differences 
(P > 0.05).  This comparison proves that, on average, the DDD does not significantly differ 
from PDD, and also that in the HNHFA database for assessing adherence the DDD and the 
refill frequency methodology can be used interchangeably.  In a comparative study, Merlo et 
al. also concluded that DDD is as suitable as PDD in pharmacoepidemiologic studies at the 
individual level [59]. 
 The adherence estimation was performed on chronically treated patients to eliminate 
bias due to in-year initiation or discontinuation of therapy.  The cohort of chronically treated 
patients was defined as patients who had at least one prescription filled in a 6-month period 
both before and after the studied year. 
 Persistence was defined as the length of time, expressed in months, between the date 
of the first prescription and the date of discontinuation (which was assumed to be 30 days 
after claiming the last prescription, as generally 1-month supplies are prescribed).  
Persistence was calculated relative to the index date (date of the first prescription).  
Persistence analysis included only newly treated patients, defined as subjects who have not 
claimed any prescription for the studied drug during the 6-month period prior the index date. 
 
4.4.  Data processing and statistical analyses 
 
The original database files from HNHFA were converted to MS Excel and the 
majority of data extraction and data processing tasks were accomplished using Visual Basic 
scripts.  Visual Basic scripts enable some degree of automation in the data processing and 
ensures the documentation and reproducibility of the steps of the research procedures. 
Student’s t-test and chi-square analysis or Fisher’s exact test were applied to compare 
means and proportions, and linear regression over time was conducted to evaluate long term 
trends in monthly and annual patient number and DDD totals.  Correlations were tested by 
Pearson correlation if data were normally distributed, and by Spearman correlation if data 
were not normally distributed.  Kolmogorov-Smirnov test was applied to assess the 
normality of the distribution.  Persistence calculations were performed by Kaplan-Meier 
survival analysis, with patients being censored at the end of their observation time if they 
were still on the therapy. 
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Seasonal patterns were identified by seasonal decomposition, and the strength of the 
seasonality was quantified by the coefficient of determination (R2Autoreg) of an autoregressive 
regression model [60]. 
A P-value <0.05 was considered significant, and all reported P-values are two-tailed.  
Statistical analyses were conducted in SPSS version 13.0 (SPSS Inc, Chicago, IL).  
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5. RESULTS 
 
5.1.  Prevalence of OAD users 
 
The prevalence of patients using OADs steadily increased during the study period 
(R = 0.970, P < 0.001).  The yearly prevalence of OAD users increased by 50% in 7 years, 
from 12,159 patients in 1998 to 18,587 patients in 2004.  During the study period a total of 
38,855 patients received any OAD treatments at least once.  In respect of the total 
population, the prevalence was 2.88% in 1998 and 4.32% in 2004.  Considering only the 
adult population, the prevalence was higher: 3.61% in 1998 and 5.51% in 2004.   
While the monthly patient number was only 5006 at the beginning of 1998, by the 
end of 2004 it reached 10597. 
 
5.2.  Incidence of OAD users and seasonality in the onset of type 2 diabetes 
 
While the prevalence was continuously rising, the yearly incidence cases did not 
display an upward trend, varying between 4204 and 4748.   
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Figure 3. The monthly number (mean ± SD) of incidence cases of type 2 diabetes and a 
fitted polynomial trend line presenting the sinusoid seasonal pattern. 
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The monthly incidence cases displayed a seasonal pattern.  The results of the 
autoregressive regression model fitted to the monthly data revealed a strong seasonality 
(R2Autoreg = 0.632).  Seasonality followed a sinusoidal pattern; the peak month was March, 
with a monthly incidence of 430.3 ± 34.0 (mean ± SD) cases, and the trough month was 
August, with a monthly incidence of 293.2 ± 23.8 cases (Figure 3).  Similar patterns were 
found in both sexes. 
 
5.3.  Patient demography 
 
There was a slight female majority of patients: 56% of patients were females and 
44% were males, which remained constant during the study period.  The average age for 
males was significantly lower (P < 0.001) than for females in each year, and gradually 
decreased in both genders.  In 1998 the average age was 64.48 years for females and 61.81 
years for males, which decreased to 63.37 and 61.16 years by 2004. 
No significant difference was found in the average age of the two genders at the 
initiation of the OAD therapy.  The average age of incidence users was 59.12 years in 1999 
and 57.39 years in 2004.   
The demographic characteristics of the 1350 patients, who met the inclusion criteria 
for detailed analyses, (including 621 males and 729 females) did not differ statistically 
(P > 0.05) from the characteristics of the total study cohort of incident users, indicating that 
the sample is representative.  
 
 5.4.  Utilization of OADs 
 
The overall consumption of OADs increased by 76% from 20.85 DDD/TID in 1998 
to 36.83 DDD/TID in 2004 (Table 2).   
The selection of OADs to prescribe from became much wider over the years: in 1998 
there were seven active ingredients formulated in 15 products (different brand name, 
strength, package size), which increased to 11 active ingredients and 42 products by 2004. 
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ATC code 1998 1999 2000 2001 2002 2003 2004
metformin A10BA02 0.161 1.363 3.883 5.768 7.449 9.559 11.200
buformin A10BA03 5.016 4.335 3.266 2.597 1.943 1.446 1.056
glibenclamide A10BB01 11.351 10.085 10.455 9.302 7.998 6.855 5.538
glipizide A10BB07 0.603 0.750 0.999 1.135 1.175 0.770 0.452
gliquidone A10BB08 0.557 0.541 0.624 0.588 0.507 0.473 0.401
gliclazide A10BB09 3.001 4.268 6.171 7.343 8.587 10.391 11.702
glimepiride A10BB12 N/A 0.017 0.351 0.788 1.165 2.324 3.939
acarbose A10BF01 0.161 0.447 0.702 1.245 1.660 2.043 2.492
rosiglitazone A10BG02 N/A N/A N/A 0.000 0.001 0.004 0.028
repaglinide A10BX02 N/A N/A N/A 0.001 0.006 0.013 0.025
nateglinide A10BX03 N/A N/A N/A 0.000 0.003 0.002 0.003
Total 20.850 21.805 26.451 28.768 30.493 33.880 36.835  
 
Table 2.  Utilization of oral antidiabetic agents in defined daily doses per 1,000 inhabitants 
per day (DDD/TID) in Csongrád County 1998-2004, N/A = product not available. 
 
  The patient level data from HNHFA allow for the assessment of the prescribed drug 
scheme, and, consequently, it can be revealed if medications are used as a single agent or in 
combination with other OADs, which cannot be studied on wholesalers’ data. During a 
12-month period 56.5% of patients received only one type of drug regime, with no changes, 
23.7% of patients had one change, and 19.8% of patients had two or more changes in their 
oral antidiabetic treatment.  As the therapeutic scheme of a patient may be changed during a 
year, for the analysis of therapeutic schemes, the treatments received in the month of July in 
each year were used.  (The month of July was chosen, because the values of this month fit 
best the linear regression fitted to the monthly patient numbers.)   The analysis disclosed that 
in 1998 monotherapy was prescribed for 74% of the patients, and the combination of 2 or 
more OADs was used by 26% of the patients.  The ratio of subjects receiving combination 
therapy slightly increased over the years, and reached 31% by 2004.  In 1998, biguanide 
monotherapy was prescribed for 9.9% of patients, while 63.3% used sulfonylurea 
monotherapy and 25% received a combination of biguanide and sulfonylurea.  In 2004, 
21.5% of patients were treated with biguanide only, 40.5% received sulfonylurea 
monotherapy, 6.8% received acarbose only, 22.0% received a combination of biguanide and 
sulfonylurea, 4.5% got acarbose and sulfonylurea, and the combination of 3 drugs from 
different therapeutic groups was taken by 3.2% of the patients.  The prescribing of irrational 
combinations (drugs from the same therapeutic class) happened in some rare cases.  
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The initial OAD treatment of new users was assessed, as well.  The vast majority of 
patients started with monotherapy: in all the studied years 91% of patients were prescribed a 
single agent, and 9% received combination therapy as an initial treatment.  In 1999 32.0% of 
patients received biguanides (18.0% metformin and 14.0% buformin), 66.5% took 
sulfonylureas (35.4% glibenclamide, 25.6% gliclazide, 2.7% glipizide, 2.2% gliquidone, 
0.6% glimepiride) and 10.0% used acarbose as an initial therapy.  In 2004 43.9% received 
biguanides (42.6% metformin, 1.3% buformin), 48.5% of patients were prescribed 
sulfonylureas (7.3% glibenclamide, 26.2% gliclazide, 0.7% glipizide, 0.5% gliquidone, 
13.8% glimepiride) and 17.5% started with acarbose. 
 
5.5.  Adherence and persistence 
  
 During the study period the adherence rate did not show any changing tendency, 
varying between 47.9% and 49.2%.  Women had a significantly better (P < 0.001) adherence 
rate than men, 51.3% vs. 45.5%.  The adherence rate peaked in patients between 60 and 79 
years and was lowest in patients in their 30s (Figure 4).  The adherence rate of patients on 
monotherapy was 40% and of those on combination therapy was 67%. 
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Figure 4.  Percentage of adherent patients in 1999 and 2003, broken down by age and 
gender. 
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The long term follow up of patients revealed that soon after the initiation of OAD 
therapy many patients discontinued the treatment.  After the first month one third of patients 
stopped taking the OADs, and after 12 months only 58.7% of them remained on the OADs.  
Persistence was found to be highly different regarding each active ingredient: it was highest 
in case of metformin (one year persistence: 62.4%), which was followed by gliclazide 
(60.2%), glimepiride (55.9%), glipizide (52.4%), acarbose (52.0%), gliquidone (37.6%) and 
buformin (34.3%) (Figure 5).  Males had slightly better persistence rate than females did.  
Persistence rate was highest in patients between 50 and 69 years, and was lower in both 
younger and older age groups. 
 
Figure 5.  Persistence with oral antidiabetic therapy (OAD), and with individual drugs. 
 
5.6.  Co-medications  
 
The complete prescription medication history of the 1350 patients (inclusion criteria 
are described in section 4.1.) gives the chance to study not only the antidiabetic medication 
of the patients, but all of their other medicines, as well.  18.0% of all prescriptions dispensed 
during the 5-year period were for medication treating diabetes (ATC A10 = OADs and 
insulins), and 82.0% were for drugs treating other health concerns.  The majority of 
medication, 42.1%, were from the ATC C main group (drugs for the cardiovascular system); 
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26.1% were from ATC A main group (drugs for the alimentary tract and metabolism) which 
include the 18.0% antidiabetic medication; 11.9% were from the ATC N main group (drugs 
for the nervous system); 6.1% were from the ATC M main group (drugs for musculo-
skeletal system); each of the other ATC main groups had a less than 3% share (Figure 6).  
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Figure 6.  Percentage of prescriptions over the 5-year period according to the ATC main 
groups. (Capital letters refer to the ATC main groups, see Table 1  for the coding) 
 
inhabitants prediabetics diabetic patients
A 4.08 2.80 13.25
B 0.81 0.80 1.49
C 4.25 12.40 21.37
D 0.03 1.04 0.97
G 0.98 0.30 0.37
H 0.23 0.29 0.40
J 0.36 1.33 1.35
L 0.06 0.02 0.06
M 1.02 2.51 3.08
N 3.03 4.32 6.06
P 0.01 0.05 0.04
R 1.25 1.06 1.34
S 0.28 0.57 1.00
V 0.00 0.01 0.01
Total 16.40 27.50 50.79
Yearly number of prescriptions perATC main 
group
 
Table 3.  Comparison of the yearly average number of prescriptions – categorized by ATC 
main groups – claimed by average inhabitants, prediabetics (patients prior the diagnosis of 
diabetes) and by diabetic patients. For diabetic patients, the yearly average of the 5-year 
study period is given. For average inhabitants, estimation is based on reference [2] and [61]. 
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During the course of diabetes – with the progression of the disease – a significant 
increase was found in the number of patients using drugs from ATC C main group 
(P < 0.001), drugs from ATC B main group (P = 0.001), drugs from ATC M main group 
(P = 0.021),  and drugs from ATC N main group (P < 0.001).  No statistically significant 
changes could be detected in cases of other medication groups. 
Diabetic patients used much more medication than the average population: they 
claimed 3 times more prescriptions than the average citizen, and nearly 2 times more than 
what they had claimed just prior their diagnoses of diabetes (Table 3). Although diabetic 
patients used more medication from most of the drug groups than the average population, the 
increase in the number of prescriptions for cardiovascular drugs (ATC C main group) was 
the most striking one.  
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Figure 7.  Number of active ingredients patients (n = 1350) used over a 5-year period. 
 
 
During the first year of diabetes males claimed 40.0 prescriptions and females 
collected 48.3 prescriptions on average.  By the fifth year this increased to 54.8 and 62.3 
prescriptions, respectively.  During the first year males used an average of 10.8 different 
active ingredients which increased to 12.9 in the fifth year, and females used 13.2 active 
agents in the first year and 14.5 in the fifth year.  During the 5-year period males were 
treated with 30.9 active ingredients, and females received 37.2 on average, but the maximum 
was 122 different active ingredients prescribed for a single patient (Figure 7).  The number 
of products patients were treated with is even higher if the different strength, package size 
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and brand names are also taken into consideration: males received 39.9 different products, 
and females were prescribed 48.4 products during the 5-year period. 
 In one third of patient–pharmacist interactions patient claimed only one prescription, 
but in nearly 20% of the pharmacy visits patients presented 5 or more prescriptions.  During 
the first year of diabetes, 5 or more prescriptions on a single visit were claimed at least once 
by 57% of patients, which increased to 72% by the fifth year. 
 
5.7.  Pharmacy visit pattern 
 
Pharmacy visit pattern analysis included 1350 patients for whom 342,854 
prescriptions were dispensed during 116,850 patient–pharmacist interactions in a 5-year 
period.  Males made significantly less pharmacy visits than females did (P < 0.001).   
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Figure 8.  Number of pharmacies patients (n = 1350) visited over a 5-year period. 
 
During the first year males made an average of 15.3 pharmacy visits, and females 
made 18.0 visits.  By the fifth year this increased to 17.5 and 19.7 visits, respectively. Each 
year patients visited an average of 3 pharmacies, and over the 5-year period 5.7 pharmacies 
(Figure 8).  No statistically significant differences were found between the two genders.  
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Patients’ loyalty to the pharmacy they most often visited was 73.5% on average.  
Strong inverse correlation (R = –0.929, P < 0.001) was found between the number of 
pharmacies in a town and patients’ loyalty.  In towns where only one pharmacy operates 
loyalty rate was 85.5%, while in Szeged, where 34 pharmacies are located, the loyalty rate 
was only 67.1%. 
Adherence rate over the time span was found to be very low: only 16.4% of males 
and 19.1% of females were adherent to the antidiabetic therapy (including both OAD and 
insulin treatments).  Increased patient loyalty resulted in significantly better adherence rates 
in females (R = 0.881, P = 0.004), but not in males (R = 0.381, P > 0.05).  Only 8.6% of 
females with less than 40% loyalty were adherent, but the adherence rate increased to 24.5% 
among females with over 80% loyalty (Figure 9). 
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Figure 9. Correlation between the degree of patient loyalty (to the pharmacy they most often 
visited) and the adherence rate. 
 
 
5.8. Cost of treatment 
 
While the utilization of OADs showed a 76% increase between 1998 and 2004, the 
expenditure increased by nearly 250%; the annual cost rose from 82.9 million Forints (HUF) 
in 1998 to 283.6 million HUF in 2004 in Csongrád County.  Some of the increase in cost 
gre  of patient loyalty 
Pe
rc
en
t o
f a
dh
er
en
t p
at
ie
nt
s 
 30
was due to inflation, but a greater part of the increase can be attributed to the higher price of 
newer products. The financial burden on patients increased more dramatically, by over 
550%.  The average reimbursement on OADs was 85% at the beginning of 1998, which 
gradually decreased to 65% by mid 2000, and remained steady since then.  In 1998 
copayment varied between 1.28 and 80.40 HUF/DDD.  The most often used product 
(Gilemal 5 mg) had a 2.00 HUF/DDD copayment.  In 2004 copayment ranged between 1.30 
and 204.38 HUF/DDD.  The largest quantity was prescribed from Diaprel, which had a 
copayment of 12.13 HUF/DDD, and the second largest quantity was prescribed from 
Merckformin 850 mg, for which patients had to pay 7.69 HUF/DDD (Table 4).   
 
copayment total cost copayment total cost
metformin 25.88–30.51 25.88–30.51 7.49–77.33 (F) 29.24–77.33
buformin 2.30 (F) 23.00 18.00 (F) 52.80
glibenclamide 2.00 (F) 20.33 12.07 (F) 39.93
glibenclamide micro 1.28–1.67 (F) 12.78–16.40 1.30–10.93 (F) 15.25–35.33
glipizide 12.00 40.07 15.80 52.53
gliquidone 11.48 38.28 11.72 45.88
gliclazide 12.20 40.67 12.13 47.40
gliclazide MR N/A N/A 14.50 56.50
glimepiride N/A N/A 24.87–30.87 58.12–72.73
acarbose 48.88–80.44 97.75–161.00 49.60–82.00 115.55–193.00
rosiglitazone N/A N/A 149.95–204.38 348.62–472.50
repaglinide N/A N/A 107.47 126.42
nateglinide N/A N/A 129.71 259.46
1998 2004
 
 
Table 4.  The cost of oral antidiabetic drugs in 1998 and 2004.  The copayments and the 
total costs are expressed in Forints per defined daily doses (HUF/DDD).  (F) indicates that 
medication was available free of charge for eligible patients.  N/A = product not available 
 
Financial support on medication was further reduced by making less people eligible 
for free medication (a form of social support).  At the beginning of 1998 one fifth of the 
prescriptions were free of charge, but at the end of 2004 this number decreased to 6.4%. 
The expenses of the OADs are only part of the total medication cost of patients with 
diabetes.  A total medication cost analysis was performed on the complete prescription 
medication record of the 1350 newly diagnosed diabetic patients. The analysis revealed that 
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antidiabetic medications (including OADs and insulins) were responsible for only 15.7% of 
the total prescription medication costs over the first 5 years of diabetes, while drugs for the 
treatment of cardiovascular diseases (ATC group C) accounted for 42.5% of all expenses.  
There were no statistically significant differences (P > 0.05) between the expenses of males 
and females during the five years, but the medication cost prior the diagnosis of diabetes was 
significantly (P = 0.001) higher for females than for males.  The overall prescription 
medication cost (copayment and insurance reimbursement) for the 5 years was, on average, 
429,448 HUF per patient.  With the progression of the disease the annual cost rapidly 
increased, and by the fifth year it was more than the double of the costs of the first year 
(Figure 10).  During the first year the average medication expense was 60,366 HUF per 
patients, which increased to 124,206 HUF by the fifth year. 
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Figure 10.  The increase of the average yearly prescription medication cost (copayment and 
insurance reimbursement) in Forints (HUF) per patient as diabetes progresses. Year -1 
represents the period prior the initiation of antidiabetic treatment. 
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6.  DISCUSSION 
 
6.1.  Prevalence 
 
The yearly prevalence of OAD users only reflect the number of patients using OADs 
and not the total number of people having diabetes, as it did not include patients who use 
insulin only, and therefore the number of people receiving any type of medical treatment for 
diabetes is expected to be about 20% higher.  According to the official health statistics, 
6.51% of the adult population of Csongrád County was registered as having diabetes in 
2003, which was slightly higher than the national average of 6.28%.  (Figure 11) [2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  Prevalence of diabetes among the adult population in 2003  (map is based on 
official national health statistics [2]) 
 
Although there was a continuously rising tendency in the monthly patient numbers, 
some distinct fluctuations were evident, which could be contributed to price changes of the 
medication patient claimed. Just before any increase in the copayment of drugs, the number 
of patients claiming their medication increased, after which transient declines of up to 15% 
in the number of patients were noted. 
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6.2.  Incidence and seasonality 
 
The incidence cases of OAD users can be considered as the incidence cases of type 2 
diabetes.  The onset of type 2 diabetes is difficult to identify and study from the point of 
view of pharmacoepidemiology, as in the earliest stage of the disorder, mostly nonmedical 
approaches are applied that are not always recorded in the medical profile.  In the 
progression of type 2 diabetes the initiation of treatment with oral antidiabetic drugs is the 
stage at which all patients can be definitively recognized as having the disorder. 
The seasonal pattern in the onset of type 1 diabetes has been described [62], but 
seasonality in the onset of type 2 diabetes has not been previously reported. Some studies 
revealed seasonal changes in glycemic control in selected cohorts of patients with type 2 
diabetes [63–65].  The months of peak and trough coincide with the peak and trough periods 
in the seasonality of HbA1c values previously reported [63].  Although the exact mechanism 
causing the seasonality is not yet known, it is thought that seasonal changes in weather, 
eating habits and physical activity may be contributing factors [63]. 
 
 
6.3.  Patient demography 
 
The female majority of patients diagnosed with diabetes in the studied population is 
the result of the demographic structure of the general population.  Females have a longer life 
expectancy than males (76.5 years for females, and 68.2 for males [66]).  Therefore, at an 
older age there is a marked female majority.  The age- and gender-specific prevalence 
reveals that males have a slightly higher prevalence of diabetes than females do. 
The decline in the average age of incidence users suggests that the onset of type 2 
diabetes is shifting to a younger age. 
The gap between the average age of prevalent users and the average age of incident 
users is getting wider, indicating that patients are now treated for a longer period of time, but 
this can be rather contributed to the earlier initiation of the treatment than to any 
improvement of life expectancy of diabetic patients.  Between 1999 and 2004 the gap 
increased from 3.01 to 4.04 years for males, and from 4.36 to 5.77 years for females, which 
indicates that after the diagnosing of diabetes females live much longer than males do. 
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6.4.  Changes in the utilization of oral antidiabetic drugs 
 
Along with the escalating patient number, the total utilization of OADs increased, as 
well.  Although the use of each therapeutic group increased, a marked restructuring was 
evident.   
The extensive increase in product number is not only the result of the broader 
selection of active ingredients, but rather due to the availability of generic drugs.  By 2004 
over one third of the total metformin use was in the form of generic products (Merkformin 
was considered as the original product which was the first metformin marketed in Hungary). 
The use of biguanides increased by 136%, but the share of the available active 
ingredients – metformin and buformin – fundamentally changed.  Buformin was the only 
biguanide on the market for two decades after its licensing in Hungary in 1967, and 
metformin was licensed only in 1996, and became available from early 1998.  In 1998 the 
vast majority of biguanide use was due to buformin, which gradually decreased, and in 2000 
the ratio switched in favor of metformin, and by 2004 metformin was responsible for over 
90% of biguanide utilization.  This is a positive change as guidelines recommend the use of 
metformin, and the application of buformin is considered to be out of date [56].  Metformin 
was prescribed, either alone or in combination with other OADs, for only 4.2% of the 
patients in 1998, whereas in 2004 it became the most often used OAD, received by 43.0% of 
patients.  Its widespread use can be justified by the fact that metformin is the first choice of 
drug in overweight patients and that in Hungary half of the adult population is overweight or 
obese [67].  Phenformin, an other representative of the biguanide group, that had been 
available in several other countries, was never marketed in Hungary. 
The use of sulfonylureas increased at a much lower scale than the use of biguanides, 
undergoing a 42% raise.  While in 1998 glibenclamide was the most often used sulfonylurea 
(and the most often used OAD, as well) with 11.35 DDD/TID, in 2002 gliclazide took the 
lead, and in 2004 only 5.54 DDD/TID glibenclamide was consumed.  In 1998 only 17% of 
the glibenclamide use was in the form of micronized glibenclamide, which gradually 
increased, and in 2004 the share of the micronized form was two thirds.  During the same 
time frame the utilization of gliclazide increased from 3.00 to 11.70 DDD/TID.  The 
modified release formulation of gliclazide became available in 2003, and in 2004 already 
over 20% of the gliclazide was used in that form.  Glimepiride was first marketed in 1999, 
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and by 2004 its use reached 3.94 DDD/TID.  The use of the other two available 
sulfonylureas (glipizide and gliquidone) remained subsidiary during the study period.  In the 
case of elderly people, the choice of sulfonylurea should be one of the short-acting ones, 
such as gliclazide, and the prescribing of the long-acting sulfonylureas, such as 
glibenclamide, should be avoided [56, 68].  Among patients 65 years of age or older, 
glibenclamide was the most often prescribed OAD in 1998, taken by 71.6% of the elderly 
patients, but in 2004 only 15.3% of the patients were using it.  In 1998, gliclazide was 
prescribed for 21.9% of the elderly patients, and in 2004 it was the most often used 
sulfonylurea, received by 40.8% of them. 
Acarbose is the only representative of the alfa-glucosidase inhibitors available on the 
Hungarian market, which was licensed in 1991.  In 1998 its use was still marginal (0.16 
DDD/TID), which only slowly increased, and reached 2.49 DDD/TID in 2004.  Its relatively 
high price (see Table 4) may explain its limited use for the several years following its 
launch.  Until the introduction of rosiglitazone and the meglinides (repaglinide, nateglinide), 
acarbose had been the most expensive OAD. Miglitol, an other alfa-glucosidase inhibitor, 
was license in Hungary in 2000, but it has not been marketed since. 
The meglinides and rosiglitazone, even after being available on the market since 
2001, still could not gain ground.  Their high price compared with other OADs was the 
likely reason that caused their use to remain marginal.  Although by the end of 2003 these 
newest OADs were accepted into the reimbursed category, their copayments were still 
exceptionally high. 
Calculation was performed in order to estimate the proportion of patients with type 2 
diabetes who were treated with insulin.  Patients were classified as described under section 
4.2.  During the study period the use of insulin did not change considerably among patients 
with type 2 diabetes.  In 1998, 16.53% were treated with insulin alone, 2.27% with the 
combination of OAD and insulin, and 81.20% with OADs.  In 2004, 16.05% were treated 
with insulin alone, 3.63% with the combination of OAD and insulin, and 80.31% with 
OADs.  The proportion of patients on combination therapy is extremely low compared with 
that of other countries.  In France, 18% were treated with insulin plus OAD, 9% with insulin, 
and 71% with OAD; in Sweden, 23% used insulin plus OAD, 3% received insulin, and 74% 
received OADs [69, 7 0]. 
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Comparing the utilization of antidiabetic drugs in Hungary to that of some other 
European countries, it is notable that the use of OADs versus insulin was high in Hungary: 
73.7% of all antidiabetic drugs were OADs, whereas in Sweden their share was only 48.5% 
in 2003 [71] (Table 5).  The theoretical exposure of each patient to antidiabetic drugs 
(calculated from the total utilization of antidiabetic drugs and from the estimated prevalence 
of patients [3, 71]) was 0.47 DDD/day in Hungary, which was similar to that of Norway 
(0.48 DDD/day).  Finland and Iceland had exceptionally good exposure rates (0.80 and 1.05 
DDD/day).  The low rate for Hungary suggests that many patients remained untreated and/or 
undermedicated. 
 
Iceland Denmark Norway Finland Sweden Hungary
Diabetes prevalence (%) 2.0 6.9 6.9 7.2 7.3 9.7
Insulins (DDD/TID) 5.9 11.3 16.5 20.2 21.7 12.11
OADs (DDD/TID) 15.1 17.2 17.2 37.8 20.5 33.88  
 
Table 5.  Estimated prevalence of diabetes in the adult population and utilization of 
antidiabetic drugs in some European Countries in 2003 [3, 71]. (DDD/TID defined daily 
doses per 1,000 inhabitants per day, OADs oral antidiabetic drugs) 
 
 
Considering the number of patients treated with OADs and the fact that about one 
fourth of them received combination therapy, the utilization of OADs should have been 
above 50 DDD/TID in 2004.  Comparing this number with the actual consumption of 36.83 
DDD/TID further supports the hypothesis that some patients did not take the desired amount 
of medication.  
 
6.5.  Adherence and persistence 
 
The crude adherence rate did not change considerably over the study period.  Women 
had a better adherence rate than man.  This fact suggests that female patients tend to manage 
their disease better and take better care of their health.  The National Health Survey of 2000 
revealed that women were 30% more likely than men to have appointments with their 
general practitioners [67].  The results of the present research show that younger age groups 
are more likely not to adhere to therapy.  The adherence rate was found to be lowest in 
patients in their 30s, although tight glycemic control would be essential from the earliest 
stage of diabetes to reduce a patient’s risk of developing chronic complications.  At younger 
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age, patients are less likely to have developed chronic complications of diabetes; therefore 
they may perceive their disease to be less serious than it is. 
The results showed that people on combination therapy had a much better adherence 
rate (67%) than those on monotherapy (40%).  This result contradicts with the general belief 
that the adherence rate decreases with the complexity of the therapy, although some studies 
support the above findings [72, 73].  It is possible that those on combination therapy had 
worse health conditions with possibly higher rates of complications, which made them take 
their situation more seriously and, consequently, made them adhere to therapy much better.  
In order to tests the hypothesis that the adherence of patients should improve with the 
progression of the disease, the adherence rate was assessed for those patients who were 
present during the entire study period.  This cohort consisted of 3771 patients, and their 
adherence was followed for a 5-year period, between 1999 and 2003.  The adherence showed 
a constantly rising tendency with the progression of time: in 1999 48.4% of males and 54.8% 
of females were adherent, which increased to 66.3% and 70.5% in 2003, respectively; 
therefore, these results support the above hypothesis. 
The rate of treatment discontinuation was high, most strikingly soon after the 
initiation of the therapy, suggesting that a considerable portion of diabetic patients find it 
difficult to accept the fact that their condition would require long term medical treatment.  In 
order to achieve long term success in the treatment, special attention should be paid to the 
patients during the early months of the therapy. 
 
6.6.  Co-medications 
 
Previous studies have proven that diabetic patients take significantly more medication 
than nondiabetic subjects [74].  The use of many drugs by a patient is referred to as 
polypharmacy, which is often defined as taking 5 or more drugs at the same time [75].  The 
increased number of medication prescribed is often the result of treating common 
comorbidities of diabetes, such as hypertension, dyslipidemia, depression, and 
coagulopathies [76]. 
The large share of drugs from the ATC C main group can be justified by the fact that 
cardiovascular diseases are over 3 times more common among diabetic patients than in 
nondiabetic ones, and it has been reported that more than 90% of diabetic patients over the a 
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age of 65 have hypertension [77].  In the present research in the last half year of the study 
period 89.5% of the patients were taking some medication for cardiovascular diseases. 
The concurrent use of several drugs not only increases the complexity of the treatment 
and results in higher health care cost, but also raises the risk of adverse drug reactions and 
drug-drug interactions [75]. As polypharmacy is almost inevitable in diabetic patients, 
regular reevaluation of the therapy is essential to minimize the risk arising from 
polypharmacy. 
Over the 5-year period the number of products patients used was 30% higher than the 
number of active ingredients, which points out that subjects had used the same active 
ingredients in products of different packaging and brand name or strength. This may further 
increase the risk of medication errors, as patients may not be aware of the fact that drugs 
with different appearance can contain the same active ingredients. 
 
6.7.  Pharmacy visit pattern 
 
Community pharmacies can play an important role in the management of chronic 
disorders by offering pharmaceutical care to their patients.  Numerous studies have proven 
that pharmaceutical care programs focusing on diabetic patients can result in improved 
glycemic control [78–81].  Periodical assessments and long term follow up of patients are 
key elements of the care programs [82, 83], the benefit of which can be experienced to the 
full extent only if patients regularly visit the same pharmacy. 
Although diabetic patients made a pharmacy visit once in every 20 days on average, the 
pharmacy visit pattern study demonstrated that in a setting where patients are free to claim 
their prescription at any community pharmacy, patients do not consistently use the services 
of a single pharmacy, but they rather tend to visit several ones.  In case of females the results 
clearly prove the beneficial effect of higher patient loyalty, resulting in better adherence rate, 
although similar effect could not be detected in case of males. 
The actual number of pharmacy visits can be higher than it was measured, as due to 
the limitation of the data source, only those patient–pharmacist interactions could be counted 
where prescription medication was claimed.  A further limitation is that the person visiting 
the pharmacy may not be the patient himself or herself, but the patient’s family member or 
caregiver.  
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 The irregular pharmacy visit pattern disrupts the continuity of the care process, and, 
consequently, reduces the effectiveness of pharmaceutical care initiatives.  
 
6.8.  Pharmacoeconomic aspects 
 
Diabetes and its complications put a high financial burden both on patients and the 
society. A cost analysis study on diabetes revealed that over 10% of the total health care 
expenses are attributed to diabetes in the U.S. [84].   The expenses of the disease are not 
limited to health care spendings, but they are attributed to both direct and indirect costs.  The 
direct costs of a chronic disease include medication, outpatient services, medical devices, 
inpatient care and long-term care [85, 86].  The indirect costs are more difficult to define and 
measure, and studies vary in methodology.  The indirect costs may include present and 
future non-medical costs, such as disability, productivity loss, or premature mortality [85].  
Diabetes and its complications result in nearly 30% loss of productivity [87].  A substantial 
amount of diabetes-related costs arise from the complications of the disease, of which 
macrovascular problems have the largest share [88].  During the first 5 years of treatment, 
85% of the costs arising from the complications are related to macrovascular complications 
[88].  European and American studies report that the direct health care expenditures are 
nearly 100% higher for diabetic patients than for non-diabetic counterparts matched by age 
and gender [84, 86].  Studies widely vary on estimating the magnitude of direct and indirect 
costs related to diabetes, the estimated share of direct costs from the total expenses ranges 
between 30 and 75% [84, 85]. Data from HNHFA allow for the cost analysis of the 
prescription drug treatment, but other components of direct and indirect costs could not be 
assessed. 
The substantial increase in the copayment could have negatively effected patients’ 
medication taking behavior, but as it was described in section 5.5., the adherence did not 
decrease over the study period. 
Although the annual total medication cost of patients more than doubled from the 
first year to the fifth year, the cost increase attributed to the progression of diabetes was 
69%, taking into consideration the 22% price increase during the 5-year period. 
There was no non-diabetic control group to compare the expenses to, but the 
medication records of the study subjects were available for the 6-month period prior the 
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initiation of antidiabetic treatment.  During that period subjects were not medicated as 
diabetic patients, therefore they could represent non-diabetic patients.  The expenses of the 
6-month period were extrapolated to 12 months to get a yearly value, which is easier to 
compare to the costs of the treatment during the diabetic period.  The yearly medication costs 
prior the diagnosis of diabetes were nearly half of the costs spent during the first year of the 
disease (there were no price changes during this period that should be taken into 
consideration), and by the fifth year the treatment of diabetic patients became almost 4 times 
more costly than it was before the diagnosis of diabetes.  Prior the diabetic period the 
average yearly medication costs were 29,217 HUF for males and 37,226 HUF for females 
(P = 0.001). 
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7.  SUMMARY 
 
 During the 7-year study period the overall utilization of OADs significantly 
increased, and it showed clearly positive and considerable changes, which were in 
concordance with national and international guidelines; although the newest additions to the  
group of OADs have not been able to gain ground. 
While the number of patients receiving treatment was consistently increasing at an 
alarming scale, unfortunately, their therapeutic cooperation remained low, which can result 
in suboptimal clinical outcomes.  The rate of early treatment discontinuation was high, and 
the adherence of patients who continued the therapy was low, and did not change during the 
study period. With increased age and progression of diabetes, patients tended to better 
adhere to the treatment plan. 
The drug treatment of patients was not limited to diabetes, but due to the high 
prevalence of comorbidities and complications of diabetes, they used 3 times more 
medication than the average population, making their treatment rather complex and costly. 
The present pharmacoepidemiologic study does not only provide data on drug 
utilization patterns, but it also revealed a new pathophysiologic aspects of diabetes, namely 
that not only type 1 diabetes has a seasonal pattern in its onset, as it has been previously 
published, but  type 2 diabetes has it, as well. 
To improve patients’ therapeutic cooperation and, consequently, improving clinical 
outcomes and reducing the development of complications of diabetes, the long term care of 
diabetic patients is essential through a joint effort of health care providers.  Pharmacists can 
play an active role in the care process by the implementation of a pharmaceutical care 
program targeting diabetic patients.   
The benefits of such program could be experienced to the full extent only if patients 
would regularly visit the same pharmacy. Although diabetic patients often make pharmacy 
visits, unfortunately, most of them are not loyal to a single pharmacy and they tend to visit 
several ones, which can disrupt the care process and reduce its effectiveness.  
The results of the present thesis support the importance of the implementation of a 
pharmaceutical care program in Hungary in the near future, and provide detailed data on the 
medication use pattern and therapeutic cooperation of patients with type 2 diabetes, which 
information can serve as a resource for the design of a long-term care program. 
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